Payment overview · 2025
General Payments
$173.23
10 reported records · 6 companies
Healthcare provider profile · identity verified
Gregory N Haase, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WARSAW, IN · NPI 1851357032
Verified facts
What the public records show
CMS Open Payments records show Gregory N Haase, DO received $173.23 in general payments during 2025 across 10 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Verquvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.33 | 33.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.20 | 31.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.21 | 9.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 8.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.47 | 8.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.43 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.23 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 52 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
309 | 73 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 832 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 659 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 633 | 187 |
| Metoprolol Succinate | Metoprolol Succinate | 560 | 162 |
| Losartan Potassium | Losartan Potassium | 540 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 130 |
| Gabapentin | Gabapentin | 437 | 124 |
| Potassium Chloride | Potassium Chloride | 433 | 126 |
| Lisinopril | Lisinopril | 397 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 117 |
| Metformin Hcl | Metformin Hcl | 344 | 111 |
| Furosemide | Furosemide | 340 | 99 |
| Omeprazole | Omeprazole | 329 | 91 |
| Eliquis | Apixaban | 309 | 73 |
| Carvedilol | Carvedilol | 301 | 94 |
| Trazodone Hcl | Trazodone Hcl | 297 | 87 |
| Montelukast Sodium | Montelukast Sodium | 283 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 73 |
| Spironolactone | Spironolactone | 227 | 76 |
| Ozempic | Semaglutide | 226 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 68 |
| Mounjaro | Tirzepatide | 219 | 35 |
| Famotidine | Famotidine | 201 | 68 |
| Sertraline Hcl | Sertraline Hcl | 194 | 56 |
| Simvastatin | Simvastatin | 191 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 61 |
| Glimepiride | Glimepiride | 186 | 55 |
| Prednisone | Prednisone | 167 | 81 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 164 | 40 |
| Jardiance | Empagliflozin | 159 | 52 |
| Meloxicam | Meloxicam | 157 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 47 |
| Warfarin Sodium | Warfarin Sodium | 142 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 138 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 137 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 44 |
| Celecoxib | Celecoxib | 109 | 34 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 107 | 39 |
| Ezetimibe | Ezetimibe | 106 | 33 |
| Clonidine Hcl | Clonidine Hcl | 97 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 20 |
| Allopurinol | Allopurinol | 95 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 92 | 22 |
| Bupropion Xl | Bupropion Hcl | 89 | 23 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 85 | 32 |
| Entresto | Sacubitril/Valsartan | 83 | 21 |
| Xarelto | Rivaroxaban | 81 | 18 |
| Cefdinir | Cefdinir | 79 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 21 |
| Synthroid | Levothyroxine Sodium | 75 | 23 |
| Buspirone Hcl | Buspirone Hcl | 71 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 19 |
| Metformin Hcl Er | Metformin Hcl | 70 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 53 |
| Alendronate Sodium | Alendronate Sodium | 65 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 17 |
| Mirtazapine | Mirtazapine | 59 | 18 |
| Atenolol | Atenolol | 57 | 17 |
| Methocarbamol | Methocarbamol | 57 | 26 |
| Midodrine Hcl | Midodrine Hcl | 57 | 16 |
| Meclizine Hcl | Meclizine Hcl | 56 | 27 |
| Farxiga | Dapagliflozin Propanediol | 55 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 50 |
| Torsemide | Torsemide | 55 | 19 |
| Fenofibrate | Fenofibrate | 53 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 21 |
| Febuxostat | Febuxostat | 50 | suppressed |
| Gemtesa | Vibegron | 50 | 18 |
| Sucralfate | Sucralfate | 50 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 49 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 47 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Ondansetron Odt | Ondansetron | 45 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Finasteride | Finasteride | 43 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 15 |
| Telmisartan | Telmisartan | 42 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 41 | suppressed |
| Klor-Con M20 | Potassium Chloride | 41 | 15 |
| Nitroglycerin | Nitroglycerin | 39 | 27 |
| Glipizide | Glipizide | 37 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | 19 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 14 |
| Prolia | Denosumab | 35 | 23 |
| Livalo | Pitavastatin Calcium | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | 13 |
| Cephalexin | Cephalexin | 33 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Lactulose | Lactulose | 30 | 15 |
| Novolog Flexpen | Insulin Aspart | 30 | 14 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | 13 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Ramipril | Ramipril | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 16 |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Verquvo | Vericiguat | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Colchicine | Colchicine | 16 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.23 · 10 records | Bayer Healthcare Pharmaceuticals Inc. | CAPVAXIVE, FARXIGA, JARDIANCE, Kerendia, QULIPTA, UBRELVY, VERQUVO, VYNDAQEL | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error